Cardiovascular Safety Study of Lodenafil Carbonate in Patients With Coronaropathy During Physical Effort

NCT ID: NCT00817830

Last Updated: 2015-07-16

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-11-30
• Study Completion Date: 2009-10-31

Brief Summary

The purpose of this study is to assess the safety of lodenafil carbonate in patients with coronaropathy, evaluating the response of the body facing physical effort, including both heart and respiratory components, with and without use of lodenafil carbonate 80mg.

Detailed Description

Phosphodiesterase 5 inhibitors (iPDE5) are effective drugs to treat erectile dysfunction (ED).

ED is linked to several factors, like advanced age and diabetes as predominant in its incidence. In addition, ED can be an early manifestation of cardiovascular diseases.

Among the iPDE5 existing in the Brazilian market there is a new molecule which called lodenafil carbonate. It was recently approve and release for use in Brazil, and has similar effectiveness and adverse reactions comparing with other drugs from the same family.

The molecule was evaluated with respect to possible changes in heart rate, blood pressure and QT interval, and the results point out excellent cardiovascular safety profile.

There is a corelated incidence between patients with coronary artery disease and erectile dysfunction. Although patients with stable angina and, under appropriate clinical treatment did not show increase in cardiovascular risks during sexual intercourse, the increased incidence of erectile dysfunction in this population determines a specific group of patients with high potential for use iPDE5.

Therefore it is essential that any new phosphodiesterase 5 inhibitors should be evaluated in patients with coronary artery disease, especially in heart rate, during physical effort.

Conditions

Erectile Dysfunction; Coronaropathy

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

lodenafil carbonate

Evaluate cardiovascular safety of lodenafil carbonate in patients with coronary artery disease undergoing physical effort, before and after using lodenafil carbonate.

Group Type: EXPERIMENTAL

lodenafil carbonate

Intervention Type: DRUG

Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.

Interventions

lodenafil carbonate

Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.

Intervention Type: DRUG

Other Intervention Names

Helleva

Eligibility Criteria

Inclusion Criteria

• Coronary artery disease with obstruction <70%, confirmed by prior catheterization, stable patient, and have already showed an acute event (unstable angina or myocardial infarction, according to the guidelines of the Brazilian Society of Cardiology) for at least 6 months;
• Age ≥ 18 and ≤ 60;
• Men;
• Stable for 6 months, regardless of previous myocardial infarction or revascularization;
• ejection fraction of doppler echocardiography ≥ 50%.

Exclusion Criteria

• Use of nitrate;
• Use of bronchodilators;
• Smoking current period or in less than 6 months;
• Hemoglobin <10 g / dL;
• Systolic pressure> 160 mm Hg and <100 mmHg;
• Diastolic pressure> 110 mm Hg and <60 mmHg;
• Body mass index (BMI)> 30;
• Symptomatic peripheral artery disease;
• Event of angina or AMI, at any time, whether I've done some examination or not;
• Finger tip blood glucose < 70 and > 200mg/dL at the time of examination;
• Chest injury > 50%;
• Triple arterial injury with surgery indication;
• Moderate or severe chronic obstructive pulmonary disease (COPD) confirmed by spirometry;
• Pulmonary hypertension with pressure > 35mmHg confirmed by doppler echocardiography;
• Moderate or important aortic and/or mitral valvulopathy confirmed by doppler echocardiography;
• Changes in enzyme markers (Troponin I) after the first test;

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Cristália Produtos Químicos Farmacêuticos Ltda.

INDUSTRY

Sponsor Role: lead

Responsible Party

Cristália Pordutos Químicos Farmacêuticos Ltda

Principal Investigators

Roberto Franken, Doctor

Role: PRINCIPAL_INVESTIGATOR

Irmandade da Santa Casa de Misericórdia de São Paulo

Locations

Irmandade da Santa Casa de Misericórdia de São Paulo

São Paulo, São Paulo, Brazil

Countries

Brazil

Other Identifiers

CRIST001

Identifier Type: -

Identifier Source: org_study_id